Phase 2 N=41 Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
Adult Idiopathic Generalized Osteoporosis
Primary: Change in Lumbar Spine Bone Mineral Density (LS-BMD) on Active Medication — 10.1; 4.1 percentage of change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=22 Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women
Menopause · Fracture · Osteoporosis
Primary: Change in Lumbar Spine Bone Density by Dual Energy X-ray Absorptiometry (DXA) — 10.8 percentage of BMD change
Phase 3 N=34 Pamidronate to Treat Osteogenesis Imperfecta in Children
Osteogenesis Imperfecta
Primary: Change in Bone Mineral Density in Response to Pamidronate — -3.54; -4.98 Z-score
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
Phase 3 N=143 Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
Osteogenesis Imperfecta
Primary: Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Month 12, ITT Population — 7.592; 16.159 Percent Change — p=<0.0001
Phase 2 N=33 Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Adult Idiopathic Generalized Osteoporosis
Primary: Percent Change in Lumbar Spine Areal BMD by DXA — 5.2 percentage of change
Phase 3 N=135 The Effect Of Oral Ibandronate In Male Osteoporosis
Male Osteoporosis
Primary: Mean Percent Change in BMD of the Lumbar Spine From Baseline to Month 12 — .94; 3.52 percent — p=<0.001
Phase 2 N=10 Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
Osteoporosis
Primary: Number of Participants With Increased Bone Mineral Density — 10 participants
Phase 4 N=78 Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Spine Bone Mineral Density (BMD) — 6.1; 2.8 percentage of change in g/cm2
Phase 3 N=24 Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With · Glucocorticoid-induced Osteoporosis
Primary: Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months — 0.23; 0.11 Z-score — p=0.68
Phase 4 N=18 Bisphosphonate Therapy for Osteogenesis Imperfecta
Osteogenesis Imperfecta · Osteoporosis · Paget Disease of Bone
Primary: Bone Mineral Density — -1.3; -1.1 z-score
N/A N=11 Alendronate in Juvenile Osteoporosis
Juvenile Osteoporosis · Low Bone Density · Fractures
Primary: Bone Mineral Density (BMD) of the Lumbar Spine (Participants With Percentage Increase). — 11 participants
Phase 3 N=428 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
Osteoporosis
Primary: Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.059; 0.028 grams per square centimeters — p=<0.001
Phase 1 N=11 Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 2; 4; 2; 1 Participants
N/A N=22 Prevention of Post Operative Bone Loss in Children
Osteoporosis · Cerebral Palsy · Spina Bifida
Primary: Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan — 0.043; -0.025 percent change
N/A N=26 Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome
Osteoporosis Pseudoglioma
Primary: pQCT of Lower Leg — -2.19; 0.04; -2.09; -0.30 Z-score — p=0.0003
Phase 3 N=42 Growth Hormone Therapy in Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
Phase 3 N=795 Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis) — 0.8; 3.8; 2.3; 4.4 percent change — p=< 0.001
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 2 N=5 ACTIMMUNE in Intermediate Osteopetrosis
Osteopetrosis
Primary: Number of Participants With Treatment Related Adverse Events CTCAE v4.0 Grade 3 or Higher — 0 Participants
Phase 2 N=12 Use of ACTIMMUNE in Patients With ADO2
Autosomal Dominant Osteopetrosis Type 2
Primary: Changes in Bone Resorption Markers From Baseline to 14 Weeks. — 2.2; -2.1 percentage of change
N/A N=77 Study of Growth Hormone and Bone in Obesity
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
Phase 4 N=45 Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
Osteoporosis
Primary: Absolute Difference in the Log-transformed CTX Values Between V4 vs. V6 — 129.15; 71.79; 107.62 log (ng/mL)
Phase 3 N=29 Secondary Prevention of Osteoporosis
Osteoporosis
Primary: Number Adherent With the Intervention — 29 participants
Phase 4 N=140 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12 — 3.2; -0.1 percent change in BMD — p=<0.001
Phase 2 N=22 Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis
Osteoporosis
Primary: Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy — 10; 9 participants
Phase 4 N=140 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment
Osteoporosis
Primary: Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) — 5.54; 5.39 percent
Phase 4 N=109 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Bone Loss · Osteoporosis · Breast Cancer
Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change
Phase 2 N=28 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa
Disorder of Bone Density and Structure, Unspecified
Primary: Change in Spine Bone Density (g/cm^2) — -0.00558 gm/cm^2 — p=0.40